Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $4.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy’s rating is based on several promising developments at Atossa Therapeutics. The company has received positive feedback from the FDA regarding its proposed dose optimization trial for endoxifen in ER+/HER2- metastatic breast cancer, which is a significant step towards filing an Investigational New Drug (IND) application. This feedback indicates a potentially more efficient regulatory pathway and aligns with the FDA’s Project Optimus, which aims to optimize oncology drug dosing for safety and efficacy.
Moreover, Atossa’s endoxifen has shown encouraging early clinical data, including improved progression-free survival in certain patient groups. The company’s financial health is also strong, with sufficient capital to support its operations well into 2027. These factors combined with the anticipated updates on clinical trials and regulatory progress contribute to McCarthy’s optimistic Buy rating for Atossa Therapeutics.
McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Capricor Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -20.4% and a 27.50% success rate on recommended stocks.
In another report released today, Craig-Hallum also maintained a Buy rating on the stock with a $4.00 price target.